Clinical Trials Logo

Filter by:
NCT ID: NCT00636168 Completed - Clinical trials for High Risk Stage III Melanoma

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

Start date: June 30, 2008
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine if ipilimumab is effective in preventing or delaying recurrence and prolongs survival after complete resection of high risk stage III melanoma

NCT ID: NCT00636064 Completed - Pain Clinical Trials

A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery

Start date: January 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of parecoxib/valdecoxib therapy and placebo/valdecoxib therapy for the treatment of pain after coronary artery bypass surgery

NCT ID: NCT00635193 Completed - Clinical trials for Ovarian Cancer, Primary Peritoneal Cancer

Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)

Start date: July 2007
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label study of liposomal doxorubicin with or without volociximab for the treatment of subjects with advanced epithelial ovarian cancer or primary peritoneal cancer relapsed after prior therapy with Plat/Taxane-based chemo. Volociximab is an anti-angiogenic integrin inhibitor being developed for the treatment of solid tumors. Preclinical data with a surrogate volociximab antibody administered as monotherapy indicate encouraging efficacy in terms of tumor reduction and anti-angiogenic effects in mouse ovarian cancer xenograft models. In clinical studies, volociximab has been evaluated in several solid tumor types, including pancreatic, renal, and melanoma, with many subjects who entered the studies with progressive disease remaining progression-free for several months. In all studies in solid tumors, volociximab has shown a favorable safety profile when administered at 10 mg/kg q2wks and more recently at 15 mg/kg qwk. A study of volociximab in combination with liposomal doxorubicin in subjects with ovarian cancer or primary peritoneal cancer who have relapsed after prior platin/taxane therapies is warranted to further evaluate the drug's efficacy and safety. The investigators have thus far activated stage 2 of this study at 11/25 sites. Worldwide, the study aims to enroll 150 subjects.

NCT ID: NCT00634088 Terminated - Clinical trials for Locally Advanced or Metastatic Breast Cancer

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Start date: June 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and preliminary effectiveness of ixabepilone plus lapatinib with and without capecitabine in the treatment of human epidermal growth factor receptor 2 (HER2)-positive or metastatic breast cancer.

NCT ID: NCT00634049 Completed - Aspergillosis Clinical Trials

Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi

VITAL
Start date: April 22, 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of isavuconazole in the treatment of renally impaired participants with invasive fungal infections caused by Aspergillus and participants with invasive fungal disease caused by rare fungi.

NCT ID: NCT00633893 Completed - Venous Thrombosis Clinical Trials

Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Start date: May 2008
Phase: Phase 3
Study type: Interventional

The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)

NCT ID: NCT00633880 Completed - Clinical trials for Dopamine Beta Hydroxylase Deficiency

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

NOH302
Start date: January 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.

NCT ID: NCT00631995 Completed - Meningitis Clinical Trials

Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers

Start date: April 2008
Phase: Phase 1
Study type: Interventional

This study is aimed at studying quadrivalent meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine (TetraMen-T) formulations in Toddlers. Primary Objectives: Safety and Immunogenicity: To describe the safety and immunogenicity profiles of: - A single dose of each formulation of TetraMen-T vaccine - A single dose of NeisVac-C® vaccine.

NCT ID: NCT00631475 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443

BUILD OL
Start date: April 2008
Phase: Phase 3
Study type: Interventional

This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF).

NCT ID: NCT00631371 Completed - Clinical trials for Renal Cell Carcinoma

Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects

INTORACT
Start date: April 2008
Phase: Phase 3
Study type: Interventional

Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa. Secondary objectives: safety, Investigator assessed PFS, objective response rate (independently assessed), and overall survival.